Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Why Viking Therapeutics Stock May Skyrocket

Timothy SykesAvatar
Written by Timothy Sykes
Updated 7/8/2025, 5:04 pm ET 6 min read

In this article

  • VKTX+0.38%
    VKTX - NASDAQViking Therapeutics Inc.
    $30.52+0.12 (+0.38%)
    Volume:  152909
    Float:  107.70M
    $30.38Day Low/High$31.00

Viking Therapeutics Inc.’s stocks have been trading up by 9.81 percent after announcing promising clinical trial results.

Study Trials for New Obesity Drug

  • Viking Therapeutics has unveiled the beginning of a significant phase 3 trial for their promising drug candidate, VK2735. The drug aims to treat obesity by targeting GLP-1 and GIP receptors in a dual agonist approach. This extensive program covers two substantial studies over 78 weeks, evaluating the potential and safety of a subcutaneous formulation.

  • Initial thoughts on the development hinted at successful outcomes from earlier trial phases. Viking’s forward-thinking extends beyond the current trial phases, with a maintenance regimen study also on the horizon. Speculation grows over the potential implications of upcoming phase 2 oral formulation results within the year.

  • Viking’s approach in obesity treatment shows continued boldness, and while this marks a pivotal moment for the company, the investor community remains keen on learning how such developments will translate into value.

Candlestick Chart

Live Update At 17:03:46 EST: On Tuesday, July 08, 2025 Viking Therapeutics Inc. stock [NASDAQ: VKTX] is trending up by 9.81%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

In-Depth Financial Overview and Recent Earnings

As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” Trading can be a complex and ever-changing landscape, where learning and adapting are critical for success. Just as Sykes highlights, accepting the fluctuating nature of the market is crucial for traders. Understanding that each setback is an opportunity to refine your approach will not only make you a more resilient trader but also enhance your ability to navigate the market effectively.

The recent stock price journey of Viking Therapeutics Inc. has pointed toward renewed investor confidence. From Jul 1, 2025, to Jul 8, 2025, stock prices witnessed an upward trajectory, closing at $30.19 from an entry of $26.67, experiencing peaks and temporary pullbacks within the span. This gathered momentum may align with increasing optimism surrounding VK2735.

Their earnings revealed nuanced figures indicating a mixed economic health. Despite a net income from continuous operations showing a negative of $45.63M, efforts in cash flow management showed results with net cash flow changes noting an increase of $11.26M. The market’s hopeful anticipations reflect not just about bottom-line figures but potential market positioning, pivoting on the forthcoming drug’s progress.

Examining financial strength ratios resonate with security – a current ratio of 44.3 implies robust short-term financial health while exhibiting a strong ability to meet short-term obligations. However, the PE ratios such as a high of -3.16 during the last five years, pinpoint business challenges yet to be fully conquered.

More Breaking News

Impact of Forefront News on Market Movement

The impending trial serves not only as a scientific endeavor but as a crucial market signal. Investors are tuning in to the tangible future earnings potential that this drug development holds. Shifts in stock price observed in recent days could be reflective of strategic portfolio decisions, possibly driven by expectations of the company’s long-term trajectory, given the positive drug news.

Expectations of competition within the pharma space additionally tone the narrative. In an industry marked by innovations and risk volatility, Viking’s bold step in obesity-targeted therapy earmarks a decisive gamble viewed by some as a laudable venture amidst prevailing industry challenges.

This forward march resonates particularly with shareholders banking on the phase 3 trials’ success translating to commercial value – a phase where risks for dilution seem ephemeral. Market eyes are set firmly on follow-up results anticipated within months, poised to further reveal an unchartered potential.

Momentum Gained and Future Outlook

The Market Eyes Viking:

  • Initiation of VK2735’s phase 3 trial has generated palpable excitement in the pharma sector, marked by voluntary interest from larger investment arms.

  • Investor dialogue is increasingly anchored on possible revenue flows from anti-obesity measures that could rival existing contenders, marking a path laden with regulatory and market endorsements.

Strategic stakeholders foresee a rising trajectory if outcomes meet efficacy hopes – enveloping a substantial market share gain. While complexities, like regulatory and pricing pressure, hover, the biotech sector’s growth remains intricately linked to novel pipelines.

Lead Us to the Next Quarter:

Anticipations rise for Viking Therapeutics as their phase 3 trials tempt a preliminary outlook for market upheavals. Investors are urged to remain observant of developmental milestones and how emerging data could buoy stock’s future positioning. Yet, weaving a mosaic of past failures and adaptable strategies amidst uncertainties appears the course lauded by counsel.

The onus now rests on how Viking stewards their scientific innovation into making tangible economic returns, retooling market dynamics, and emboldening investment blueprints for years to come against a backdrop of dynamic management actions woven into the financial fabric.

Conclusion

Viking Therapeutics’ light showcases the regenerative power of strategic scientific dedication laced with persistent competitive fervor. The market’s eye keenly watches if the ongoing story lends itself to a tender swelled by expectations, further validating research-rich narratives from discovery through drug application. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This mentality resonates deeply in the trading world, especially as speculative winds sway, and only time will tell the eventual path paved by their ambitious undertaking in the quest against obesity, framing the tale of Viking’s resilience.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity.
Read More

In this article (YTD Performance)


* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications